Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
IPO Year: 2015
Exchange: NASDAQ
Website: salariuspharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 8/25/2021 | $5.00 | Buy | HC Wainwright & Co. |
10-Q - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
DEFA14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
DEF 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
10-Q - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
424B5 - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who previously failed or relapsed after hypomethylating agent therapy Median overall survival was 18.5 months (95% CI, range 6.1-30.9 months) with median event-free survival of 7.2 months (95% CI, range 6.3-8.2 months) HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degrad
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Salarius' common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X404 and the Company's existing trading symbol "SLRX." The reverse stock split is intended to enable Salarius to regain compliance with the $1.00 minimum c
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures to Extend Cash Runway HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2023 and provided a business update. Financial Highlights Net loss for the fourth quarter of 2023 was $0.9 mi
Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2 clinical trials in hematologic cancers and Ewing sarcoma HOUSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, today announced that its Board of Directors is implementing a series of additional cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025. These measures will allo
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,773,080, titled "Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same." This patent covers the composition of matter for novel molecular glue degraders and expires in mid-2039. As reported on August 8, 2023, Salarius retained Canaccord Genuity, LLC to lead a compreh
HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as active and recruiting on clinical trials.gov – trial NCT04734990. Salarius also announces that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a 30% decrease in the sum of diameters of the patient's target lesions, bringing the objective response rate (ORR) in Ewing sarcoma first-relapse patients to 60%, with a 60% disease co
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities were identified; Salarius intends to submit an amended Ewing sarcoma clinical trial protocol HOUSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to receive guidance regarding the development program for seclidemstat to treat Ewing sarcoma. The Company has received the final meeting minut
FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2023 and provided a business update. Financial and Business Highlights Cash and cash equivalents
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. "The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review of each program's future funding needs and the current financial markets, the Board of Directors has made the difficult decision to limit further drug development while we explore strategic alternati
The trial will assess the safety and preliminary efficacy of Salarius' novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be more likely to respond HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces U.S. Food and Drug Administration (FDA) clearance of the company's investigational new drug (IND) applicat
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00
HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,
HOUSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will report its second quarter 2022 financial results after the close of the market on Friday, August 5, 2022 and host a conference call and live audio webcast the following Monday, August 8, 2022, at 11:00 a.m. ET, to discuss its financial results for the three months ended June 30, 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Conference Call Information: Interested participants and in
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein inhibition, a clinical-stage reversible LSD1 inhibitor Multiple potential development and data milestones expected from both programs in 2H 2022 2022 Annual Meeting of Stockholders announced for June 15, 2022; Company is encouraging all stockholders to participate and vote their shares of Salarius Pharmaceuticals stock. Conference Call and Live Audio Webcast Scheduled for Today, May 12, 2022, 5:00 p.m. ET HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX),
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webcast on Thursday, May 12, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the three months ended March 31, 2022. Conference Call Information: Interested participants and investors may access the conference call by dialing either: (833) 423-0481 (U.S.)(918) 922-2375 (International)Conference ID: 8798303 An audio webcast will be accessible via the Investors Events and Presentations
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing with updates from two Phase 1/2 clinical trials in sarcoma and hematologic cancer patients anticipated in 2022 Conference Call and Live Audio Webcast Scheduled for Today, March 10, 2022, 5:00 p.m. ET HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported important corporate events and its financial results for the full year an
HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webcast on Thursday, March 10, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the three and 12 months ended December 31, 2021. Conference Call Information: Interested participants and investors may access the conference call by dialing either: (833) 423-0481 (U.S.)(918) 922-2375 (International)Conference ID: 7375449 An audio webcast will be accessible via the Investors Events and
Transformative acquisition significantly expands Salarius' oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area of cancer drug development with multi-billion-dollar market potential.Acquisition includes a lead candidate, SP-3164 (formerly DRX-164), additional protein degrader programs, and the related intellectual property portfolio that includes issued composition of matter patents.SP-3164 is expected to enter the clinic in 2023. HOUSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for pati
Cash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat Added Five New Clinical Sites to Sarcoma Trial; 13 Active Sites Now Supporting Enrollment Initial Ewing Sarcoma Combination Therapy Safety Lead-in Cohort Fully Enrolled, FET-Rearranged Sarcoma Patient Enrollment Continuing Conference Call and Live Audio Webcast Scheduled for Today, November 4, 2021, 5:00 p.m. ET HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and s
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 40,064.06 while the NASDAQ fell 1.25% to 17,124.88. The S&P 500 also fell, dropping, 0.38% to 5,406.26. Check This Out: Jim Cramer: This Tech Stock Is ‘Absolutely Terrific,’ But Jumia? It’s Not Making A Lot Of Money Leading and Lagging SectorsReal estate shares jumped by 1.4% on Wednesday. In trading on Wednesday, information technology shares fell by 2.5%. Top Headline Honeywell International Inc. (NASDAQ:HON) reported second-quarter results and lowered FY24 EPS guidance. Adjusted EPS was $2.49 (+8% Y/Y), beat
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
Shares of Tellurian Inc. (NASDAQ:TELL) rose sharply in today's pre-market trading after Woodside Energy announced plans to acquire the company for $900 million in all-cash deal. The implied enterprise value is around $1,200 million. Tellurian shares jumped 65% to $0.9422 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Netcapital Inc. (NASDAQ:NCPL) rose 43.8% to $0.1495 in pre-market trading after jumping more than 12% on Friday. Netcapital, last week, announced the launch of the beta version of its secondary trading platform. Serve Robotics Inc. (NASDAQ:SERV) gained 36.8% to $10.33 in pre-market trading. Serve Robotics shares jumped
Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from Benzinga Pro. Selective Insurance Group shares dipped 14.8% to $85.40 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Augmedix, Inc. (NASDAQ:AUGX) shares jumped 148.8% to $2.28 after the company announced it will be acquired by Commure. 60 Degrees Pha
Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results. Intuitive Surgical reported second-quarter revenue of $2.01 billion, beating the consensus estimate of $1.97 billion. The robotic-assisted surgery company reported quarterly adjusted earnings of $1.78 per share, beating analyst estimates of $1.54 per share. Intuitive Surgical shares jumped 6.7% to $444.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Serve Robotics Inc. (NASDAQ:SERV) gained 68.4% to $4.43 in pre-market trading after gaining over 12% on Thursday.
- 8K Filing
Gainers CNS Pharma (NASDAQ:CNSP) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $2.2 million. Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 37.23% to $1.29. The company's market cap stands at $24.3 million. Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 21.37% to $1.59. The company's market cap stands at $1.5 million. Salarius Pharmaceuticals (NASDAQ:SLRX) stock increased by 13.63% to $2.5. The market value of their outstanding shares is at $1.4 million. Absci (NASDAQ:ABSI) stock increased by 13.46% to $3.37. The company's market cap stands at $381.0 million. Traws Pharma (NASDAQ:TRAW) stock increased by 12.32% to $
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday. Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday. Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5%